Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 193

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 193
---
The Merger Agreement-Conversion
Ratio” (the “Conversion Ratio”). Immediately following the closing of the Merger, stockholders of DiamiR and existing
Aptorum shareholders will own approximately 70% and 30%, respectively, of the outstanding shares of the Combined Company.

The Merger Agreement contains customary representations and warranties
of the parties thereto, as well as certain covenants governing the conduct of each parties respective business between the date of the
Merger Agreement and the Closing or the earlier termination of the Merger Agreement. The Merger Agreement also includes customary closing
conditions, including shareholder approval of certain matters related to the Merger and Aptorum maintaining a certain amount of cash balance
and working capital.

The Merger Agreement contains customary representations and warranties
and agreements and obligations, conditions to closing and termination provisions. The foregoing descriptions of terms and conditions of
the Merger Agreement, Management Services Agreement, Intellectual Property License Agreement, voting and Support Agreement and Stockholders
Agreement do not purport to be complete and are qualified in their entirety by the full text of the form of the such documents which are
attached hereto as exhibits.

<div align='center'>103</div>

About DiamiR

DiamiR was incorporated in Delaware on June 16, 2014, and primarily
operates through its wholly owned subsidiary, DiamiR, LLC, which was incorporated as a limited liability company in Delaware on September
17, 2009. DiamiR is a molecular diagnostics company focused on developing and commercializing minimally invasive tests for early detection
and monitoring of neurodegenerative diseases, such as mild cognitive impairment and Alzheimer’s disease, rare neurodevelopmental
diseases, such as Rett syndrome, other brain health disorders, and cancer. The proprietary platform technology developed at DiamiR and
protected by over 50 issued patents is based on quantitative analysis of organ-enriched microRNAs detectable in blood plasma. In addition
to blood-based microRNA panels, as part of its biopharma services DiamiR’s CLIA/CAP-certified laboratory offers protein and genetic
biomarker analyses for screening, patient stratification, disease and treatment monitoring.

<div align='center'>Factors Affecting our Results of Operations</div>

Research and Development Expenses

We believe our ability to successfully develop innovative drug candidates
will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Creating high quality
global first-in